**Core Concept**
Von Hippel-Lindau (VHL) syndrome is a genetic disorder characterized by the development of multiple benign and malignant tumors, including hemangioblastomas in the central nervous system, retinal angiomas, renal cell carcinoma, pheochromocytomas, and pancreatic neuroendocrine tumors. The syndrome is caused by mutations in the VHL gene, which is a tumor suppressor gene that regulates the cell cycle and apoptosis.

**Why the Correct Answer is Right**
The VHL gene product, pVHL, is a ubiquitin ligase that targets hypoxia-inducible factor alpha (HIF-α) for degradation. In the absence of functional pVHL, HIF-α accumulates and activates transcription of genes involved in angiogenesis, including vascular endothelial growth factor (VEGF). This leads to the formation of hemangioblastomas and other vascular tumors characteristic of VHL syndrome.

**Why Each Wrong Option is Incorrect**
**Option A:** Renal cell carcinoma is a common feature of VHL syndrome, typically presenting as bilateral cystic disease or clear cell carcinoma.
**Option B:** Pheochromocytomas are a component of VHL syndrome, often presenting as bilateral adrenal masses.
**Option C:** Pancreatic neuroendocrine tumors are also seen in VHL syndrome, often presenting as insulinomas or gastrinomas.

**Clinical Pearl / High-Yield Fact**
A key feature of VHL syndrome is the development of hemangioblastomas in the central nervous system, which can present as seizures, cerebellar ataxia, or visual field defects. Remember to consider VHL syndrome in the differential diagnosis of multiple tumors or in patients with a family history of the disease.

**Correct Answer: A. Hemangioblastomas are not seen in von Hippel-Lindau syndrome.